1Not available in the United States. Binds to GIP and GLP1 receptors excursions: Increases glucose­ mediated insulin release, lowers glucagon levels, slows gastric emptying, decreases appetite diabetes vomiting, diarrhea, anorexia, weight loss, pancreatitis, C­cell tumor in rodents DIPEPTIDYL PEPTIDASE­4 (DPP­4) INHIBITORS • Alogliptin, linagliptin, saxagliptin1, sitagliptin, vildagliptin1 Block degradation of GLP­1, raise circulating GLP­1 levels Reduces post­meal glucose excursions: Increases glucose­ mediated insulin release, lowers glucagon levels, slows gastric emptying, decreases appetite Type 2 diabetes Oral • half­life ∼12 h • 24–h duration of action • Adverse effects: Rhinitis, upper respiratory infections, headaches, joint pain, pancreatitis, rare allergic reactions SODIUM­GLUCOSE CO­TRANSPORTER 2 (SGLT2) INHIBITORS • Canagliflozin, dapagliflozin, empagliflozin, ertugliflozin Block renal glucose resorption Increase glucosuria, lower plasma glucose levels Type 2 diabetes Oral • half­life ∼10–14 h • Adverse effects: Genital and urinary tract infections, polyuria, pruritus, thirst, osmotic diuresis, constipation ISLET AMYLOID POLYPEPETIDE ANALOG • Pramlintide Analog of amylin: Binds to amylin receptors Reduces post­meal glucose excursions: Lowers glucagon levels, slows gastric emptying, decreases appetite Type 1 and type 2 diabetes Parenteral (SC) • rapid onset • half­life ∼48 min • Adverse effects: Nausea, anorexia, hypoglycemia, headache BILE ACID SEQUESTRANT • Colesevelam hydrochloride Bile acid binder: Lowers glucose through unknown mechanisms Reduces glucose levels Type 2 diabetes Oral • 24­h duration of action • Adverse effects: Constipation, indigestion, flatulence DOPAMINE AGONIST • Bromocriptine D2 receptor agonist: Lowers glucose through unknown mechanism Reduces glucose levels Type 2 diabetes Oral • 24­h action • Adverse effects: Nausea, vomiting, dizziness, headache